论文部分内容阅读
目的主要观察β受体阻滞剂对慢性心力衰竭(CHF)的临床疗效及安全性。方法将60例CHF患者随机分为β受体阻滞剂治疗组和常规治疗组。β受体阻滞剂治疗组在常规抗心衰治疗的基础上加用β受体阻滞剂倍他乐克;常规治疗组用强心剂、利尿剂+卡托普利治疗,对两组患者进行3年随访观察。结果β受体阻滞剂治疗组在心功能、超声指标、24小时动态心电图及6分钟步行距离均较常规组有明显改善。结论β受体阻滞剂对CHF的治疗有显著效果。
Objective To observe the clinical efficacy and safety of β-blocker on chronic heart failure (CHF). Methods Sixty CHF patients were randomly divided into β-blocker treatment group and conventional treatment group. β-blockers in the treatment group on the basis of conventional anti-heart failure plus β-blockers betametabol; conventional treatment group with tonic, diuretics + captopril treatment of two groups of patients 3 years follow-up observation. Results β-blockers treatment group in the heart function, ultrasound, 24-hour Holter monitoring and 6-minute walking distance than the conventional group were significantly improved. Conclusion β-blockers have a significant effect on the treatment of CHF.